The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

OMB APPROVAL OMB Number: 3235-0076

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

Notice of Exempt Offering of Securities

,			
1. Issuer's Identity			
	Previous		
CIK (Filer ID Number)	Names	None	Entity Type
0001829635			Corporation
Name of Issuer			Limited Partnership
Transcode Therapeutics, Inc.			Limited Liability Company
Jurisdiction of Incorporation/O	rganization		General Partnership
DELAWARE			Business Trust
Year of Incorporation/Organiza	ation		Other (Specify)
Over Five Years Ago			
Within Last Five Years (S	specify Year)		
Yet to Be Formed			
2. Principal Place of Busines	s and Contact Information		
Name of Issuer			
Transcode Therapeutics, Inc.			
Street Address 1		Street Address 2	
6 LIBERTY SQUARE, #2382			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
BOSTON	MASSACHUSETTS	02109	857-837-3099
3. Related Persons			
Last Name	First Name		Middle Name
Fitzgerald	Thomas		A.
Street Address 1	Street Address 2	2	
6 Liberty Square, #2382			
City	State/Province/C	Country	ZIP/PostalCode
Boston	MASSACHUSET	TS	02109
Relationship: Executive C	Officer 🕡 Director 🔲 Promo	oter	
Clarification of Response (if Ne	ecessary):		
Last Name	First Name		Middle Name
Manting	Erik		madio Name
Street Address 1	Street Address 2)	
6 Liberty Square, #2382			
City	State/Province/C	Country	ZIP/PostalCode
Boston	MASSACHUSET	-	02109
Relationship: Executive C			
Clarification of Response (if Ne	ecessary):		
Loot Nama	First Name		Middle Neme
Last Name Marquet	First Name Magda		Middle Name
Street Address 1	Street Address 2)	
6 Liberty Square, #2382	Street Address 2	-	
	State/Province/C	Country	ZIP/PostalCode
City Boston	MASSACHUSET	-	02109
Relationship: Executive C			02107
Clarification of Response (if Ne			
Ciamication of tresponse (II IV	20033ai y j.		

Last Name	First Name	Middle Name
Calais	Philippe	
Street Address 1	Street Address 2	
6 Liberty Square, #2382		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02109
Relationship: Executive Officer D	Pirector Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	☑ Biotechnology	
Commercial Banking	Health Insurance	Restaurants
Insurance		Technology
Investing	Hospitals & Physicians	Computers
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes No	Construction	Tourism & Travel Services
Other Banking & Financial Servi	ces REITS & Finance	
Business Services	Residential	Other Travel
Energy		Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Value Ra	ange
▼ No Revenues	No Aggregate Net Asset \	/alue
1 \$1 - \$1,000,000	[] \$1 - \$5,000,000	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,00	0
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,0	00
Over \$100,000,000	Over \$100,000,000	
Decline to Disclose	Decline to Disclose	
Not Applicable	Not Applicable	
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)	
	Investment Company A	ct Section 3(c)
	Section 3(c)(1)	Section 3(c)(9)
Rule 504(b)(1) (not (i), (ii) or (iii))		
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)
Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
_	Section 3(c)(7)	[
	[<u></u>] Section 3(c)(7)	
7. Type of Filing		
New Notice Date of First Sale 2024-	12-02 First Sale Yet to Occur	

Amendment		
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes No	
9. Type(s) of Securities Offered (select all that apply)		
Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant of Right to Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities or Other Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combinenger, acquisition or exchange offer?	nation transaction, such as a Yes No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 US	D	
12. Sales Compensation		
Recipient	Recipient CRD Number None	
The Benchmark Company LLC	000022982	
(Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD Number None	
None	None	
Street Address 1	Street Address 2	
150 E 58th Street	17th Floor	
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10155
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	10133
Recipient A.C. P. / Alliance Clabel Portners	Recipient CRD Number None	
A.G.P./Alliance Global Partners		
(Associated) Broker or Dealer V None	(Associated) Broker or Dealer CRD Number V None	
None	None	
Street Address 1	Street Address 2	
88 Post Road West	2nd Floor	
City	State/Province/Country	ZIP/Postal Code
Westport	CONNECTICUT	06880
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$8,000,000 USD or Indefinite		
Total Amount Sold \$8,000,000 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
	d to porcono who do not suplify an accordity discussion.	
enter the number of such non-accredited investors who alr	d to persons who do not qualify as accredited investors, and ready have invested in the offering.	
	or may be sold to persons who do not qualify as accredited	6
15. Sales Commissions & Finder's Fees Expenses		

Provide separately the amounts of sales commissions and finders fees expenses	s, if any	y. If the amount of an expenditure is not kn	own, provide
an estimate and check the box next to the amount.			

Sales	Commissions	\$320,000 USD	Estimate
	Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

The Benchmark Company LLC acted as the exclusive placement agent for the Private Placement and the Company paid them a cash fee. Also, the Company engaged A.G.P./Alliance Global Partners as financial advisor and paid them an expense fee and a cash fee.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Transcode Therapeutics, Inc.	/s/ Thomas A. Fitzgerald	Thomas A. Fitzgerald	Interim Chief Executive Officer; Chief Financial Officer	2024-12-12

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.